Cytek Biosciences Inc – Quartalsfinanzdaten (NASDAQ:CTKB) | MetaTrader

Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik

Vierteljährlich Jährlich

Mittelzufluss aus laufender Geschäftstätigkeit 2 M-125 K108 K-3.9 M-771 K -4.69 M Mittelzufluss aus Investitionstätigkeit -63.43 M9.45 M-16.41 M18.92 M-1.84 M 10.12 M Zahlungsströme aus der Finanzierungstätigkeit -3.64 M-11.54 M-2.6 M1.94 M-1.23 M -13.43 M Freier Cashflow 1.09 M-976 K-1.54 M-4.55 M-1.8 M -8.88 M

Nachrichten

Cytek Biosciences at TD Cowen Health Care: Strategic Growth Insights

Cytek Biosciences, Inc. (CTKB) Q4 2025 Earnings Call Transcript

Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates

Cytek Biosciences earnings missed by $0.32, revenue topped estimates

Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:CTKB) 2026-01-15

Cytek Biosciences, Inc. (CTKB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Cytek Biosciences Is A Speculative Buy On Recurring Revenue Growth (CTKB)

Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday - Beyond Meat (NASDAQ:BYND), Avadel Pharmaceuticals (NASDAQ:AVDL)

Cytek Biosciences, Inc. (CTKB) Q3 2025 Earnings Call Transcript

Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates

Cytek Biosciences: EPS verfehlt Schätzungen um 0,01 $ - Umsatz besser als erwartet

Alvotech (ALVO) Surges 8.6%: Is This an Indication of Further Gains?